The Gynecologic Oncology Group
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1970-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.gog.org
Clinical Trials
195
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (165 trials with phase data)• Click on a phase to view related trials
Abemaciclib and Letrozole to Treat Endometrial Cancer
- Conditions
- Endometrial Cancer
- Interventions
- First Posted Date
- 2020-05-19
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 53
- Registration Number
- NCT04393285
- Locations
- 🇺🇸
University of South Alabama Mitchell Cancer Center, Mobile, Alabama, United States
🇺🇸Alaska Women's Cancer Care, Anchorage, Alaska, United States
🇺🇸Smillow Cancer Care at Greenwich, Greenwich, Connecticut, United States
Ribociclib and Letrozole Treatment in Ovarian Cancer
- Conditions
- Low Grade Serous Carcinoma
- Interventions
- First Posted Date
- 2018-09-17
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 51
- Registration Number
- NCT03673124
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸UF Heath, Gainesville, Florida, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
Pazopanib for Treating Uterine Leiomyosarcoma
- First Posted Date
- 2015-03-04
- Last Posted Date
- 2015-11-18
- Lead Sponsor
- Gynecologic Oncology Group
- Registration Number
- NCT02378142
Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer
- Conditions
- Recurrent Uterine Corpus CarcinomaEndometrial AdenocarcinomaEndometrial Serous AdenocarcinomaEndometrial Undifferentiated CarcinomaStage III Uterine Corpus Cancer AJCC v7Stage IIIA Uterine Corpus Cancer AJCC v7Stage IIIB Uterine Corpus Cancer AJCC v7Stage IIIC Uterine Corpus Cancer AJCC v7Stage IV Uterine Corpus Cancer AJCC v7Stage IVA Uterine Corpus Cancer AJCC v7
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Placebo AdministrationOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2014-02-19
- Last Posted Date
- 2021-09-30
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 469
- Registration Number
- NCT02065687
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸Tennessee Valley Gynecologic Oncology, Huntsville, Alabama, United States
🇺🇸Cancer Center at Saint Joseph's, Phoenix, Arizona, United States
Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
- Conditions
- Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
- First Posted Date
- 2012-11-02
- Last Posted Date
- 2021-10-20
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 30
- Registration Number
- NCT01720173
- Locations
- 🇺🇸
Poudre Valley Hospital, Fort Collins, Colorado, United States
🇺🇸Hartford Hospital, Hartford, Connecticut, United States
🇺🇸The Hospital of Central Connecticut, New Britain, Connecticut, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 38
- Next
News
Dr. Carol Aghajanian: Pioneering Patient-Centric Innovation in Gynecologic Cancer Treatment
• Dr. Carol Aghajanian has made significant contributions to gynecologic oncology through groundbreaking research in PARP inhibitors and immunotherapy combinations, revolutionizing treatment standards for ovarian and endometrial cancers. • As chief of Gynecologic Medical Oncology at Memorial Sloan Kettering Cancer Center, she has fostered a culture of mentorship and collaborative research, emphasizing the importance of patient-centered care in advancing scientific discoveries. • Her leadership in major clinical trials, including ARIEL3 and NRG-GY018/KEYNOTE-868, has led to new standard-of-care treatments, particularly in maintenance therapy and immunotherapy combinations for gynecologic cancers.
Geographic Disparities in Gynecologic Cancer Trials Impact Vulnerable Populations
A recent study reveals significant geographic disparities in the availability of gynecologic cancer clinical trials across the U.S.